Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EHMT2 | Q96KQ7 | 5/20 | 0.47 |
| ▸ | CASP1 | P29466 | 2/20 | 0.45 |
| ▸ | CASP5 | P51878 | 2/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | BACE1 | P56817 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | CASP4 | P49662 | 1/20 | 0.42 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.42 |
| ▸ | DRD4 | P21917 | 1/20 | 0.42 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.41 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.41 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | NSD2 | O96028 | 2/20 | 0.40 |
| ▸ | NSD3 | Q9BZ95 | 2/20 | 0.40 |
| ▸ | EHMT1 | Q9H9B1 | 2/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6764902 | 0.83 | KDM4E (0.40) | RAB9AMAPTNPSR1 | |
| SCHEMBL6762841 | 0.81 | ZAP70 (0.42) | MAPTNPSR1ALDH1A1HPGD | |
| SCHEMBL6764961 | 0.81 | ADRB1 (0.45) | MAPTALDH1A1TP53HPGDTSHR | |
| SCHEMBL6767219 | 0.80 | ALDH1A1 (0.51) | ACHEDRD4NPC1RAB9AMAPT | |
| SCHEMBL6765566 | 0.79 | AKR1C3 (0.45) | CASP1RAB9AALDH1A1TP53HPGD | |
| SCHEMBL6771618 | 0.79 | CKS1B (0.52) | TLR9TLR7 | |
| SCHEMBL6765711 | 0.78 | CFD (0.39) | EHMT2RAB9AMAPTNPSR1 | |
| SCHEMBL10614842 | 0.78 | EHMT2 (0.61) | EHMT2ACHEBACE1SLC2A1NSD2 | |
| SCHEMBL6766366 | 0.78 | ALDH1A1 (0.54) | ACHEDRD4NPC1RAB9AMAPT | |
| Hydrochloric Acid SCHEMBL10616130 | 0.77 | EHMT2 (0.60) | EHMT2ACHEBACE1SLC2A1NSD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6750214-B2 | PARTICULARLY IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA | COLLIS ALAN JOHN (US) | 2004-06-15 | — | — | US | disclosed |
| US-20030220332-A1 | Quinoline and quinazoline compounds useful in therapy | PFIZER INC. | 2003-11-27 | — | — | US | disclosed |
| US-6642242-B2 | Antiproliferative agents to treat benign prostatic hyperplasia | PFIZER INC. | 2003-11-04 | — | — | US | disclosed |
| US-20020049322-A1 | Quinoline and quinazoline compounds useful in therapy | COLLIS ALAN JOHN (GB) | 2002-04-25 | — | — | US | disclosed |
| US-6103738-A | Quinoline and quinazoline compounds useful in therapy | PFIZER INC. (US) | 2000-08-15 | — | — | US | disclosed |
| EP-0877734-B1 | QUINOLINE AND QUINAZOLINE COMPOUNDS USEFUL IN THERAPY | PFIZER RES & DEV (IE) | 2000-07-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049322-A1 | Quinoline and quinazoline compounds useful in therapy | NQO2, RFT1, IDH3B | EHMT2 2900/4885CASP1 2080/4885CASP5 2541/4885 |
| US-20030220332-A1 | Quinoline and quinazoline compounds useful in therapy | NQO2, RFT1, ADRB3 | EHMT2 2892/4885CASP1 2232/4885CASP5 2658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.